There were 16 acquisitions of companies with small molecule drug assets in 2021 and one merger. Here is a more in-depth look into all of the lead small molecules acquired in 2021, including a review of:
- The lead molecules in each acquisition and their structural representations where disclosed
- The mechanism of action, stage, and indication of each lead molecule
- Relevant clinical data and rationale for each acquisition
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.
Navigate the 2021 M&A Series
Work smarter in two minutes. Join >4,000 drug hunters from every major biopharma company in the world getting drug discovery updates through our Drug Hunter e-mail newsletter. Unsubscribe anytime.
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck
- Sanofi
- GlaxoSmithKline
- AbbVie
- Eli Lilly
- Boehringer Ingelheim
- Amgen
- Bristol-Myers Squibb
- Gilead
- AstraZeneca
- Teva
- Novo Nordisk
- Merck KGaA
- Takeda
- Celgene (BMS)
- Biogen
- Astellas
- Daiichi Sankyo
- Regeneron
- UCB
- Eisai
- Servier
- Kyowa Kirin
- Shionogi
- Vertex
- Lundbeck
- Taisho
- Ono
- Seagen
- Incyte
- LEO Pharma
- Janssen
- Galapagos
- Idorsia
- Astex
- Arvinas
- Kymera
- Relay
- Schrodinger
- Mirati
- Revolution
- Nimbus
- Plexxikon
- Forma
- Arcus
- RA Capital
- ARCH Venture Partners
- MPM Capital
- Orbimed
- The Column Group
- 5AM Ventures
- Versant Ventures
- Deerfield
- Goldman Sachs
- Citi
- Piper Sandler
- Softbank
- …and hundreds of others